23668-00-0

Upstream product

• 79-37-8 oxalyl dichloride 
• 1459-93-4 dimethyl Isophthalate 
• 3441-03-0 3-(methoxycarbonyl)benzoyl chloride 
• 74-89-5 methylamine 
• 1877-71-0 benzene 1,3-dicarboxylic acid monomethyl ester 
• 4376-18-5 Monomethyl phthalate 

Downstream Products

• 69383-73-9 3-(N-methylaminomethyl)-benzenemethanol 
• 23754-43-0 3-(methylcarbamoyl)benzoic acid 
• 1440210-04-7 C₉H₁₀N₂O₃ 
• 69384-33-4 C₁₄H₂₂N₄O₂S 
• 69497-57-0 2-(3-Methylaminomethyl-benzylsulfanyl)-ethylamine 

Relevant academic research and scientific papers

Induced europium CPL for the selective signalling of phosphorylated amino-acids and: O -phosphorylated hexapeptides

Two bright, europium(iii) complexes based on an achiral heptadentate triazacyclononane ligand bearing two strongly absorbing chromophores have been evaluated for the selective emission and CPL signalling of various chiral O-phosphono-anions. Binding of O-

Quinoline-based compound and selective androgen receptor agonist comprising the same

Provided are a novel quinoline-based compound, a pharmaceutical composition containing the quinoline-based compound, and a method for producing the quinoline-based compound. The quinoline-based compound acts on an androgen receptor to increase activities of the androgen receptor, and thus can be favorably used as an agent for treating and preventing diseases or conditions, in which the increased activities of the androgen can lead to improvement of symptoms or the responsiveness to treatment, for example, various hormone-related diseases of the male or female, muscle-wasting disease, osteoporosis, and the like.COPYRIGHT KIPO 2016

Discovery of the first histone deacetylase 6/8 dual inhibitors

We disclose the first small molecule histone deacetylase (HDAC) inhibitor (3, BRD73954) capable of potently and selectively inhibiting both HDAC6 and HDAC8 despite the fact that these isoforms belong to distinct phylogenetic classes within the HDAC family of enzymes. Our data demonstrate that meta substituents of phenyl hydroxamic acids are readily accommodated upon binding to HDAC6 and, furthermore, are necessary for the potent inhibition of HDAC8.

ANTITHROMBOTIC AGENTS

Compounds of formula (I): Are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisa

Antithrombotic agents

Compounds of formula (I) : are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilis

PHARMACOLOGICALLY ACTIVE AMINOALKYLPHENYL COMPOUNDS AND THEIR USE

Compounds of the general formula: STR1 and physiologically acceptable salts, and hydrates, N-oxides and bioprecursors of such compounds and such salts in whichR 1 and R 2, which may be the same or different, represent hydrogen or lower alkyl, cycloalkyl, aralkyl or lower alkenyl groups, or lower alkyl groups interrupted by an oxygen atom or a group STR2 in which R 4 represents hydrogen or lower alkyl; or R 1 and R 2 may, together with the nitrogen atom to which they are attached form a heterocyclic ring which may contain the hetero functions--O--and STR3 R 3 represents hydrogen, lower alkyl, alkenyl or alkoxyalkyl; X represents--O--,--S--or--CH 2--or STR4 where R 5 is hydrogen or lower alkyl; Y represents =S, =O, =NR 6 or =CHR. sub.7 ;in which R 6 represents hydrogen, nitro, cyano, lower alkyl, aryl, arylsulphonyl or lower alkylsulphonyl; R 7 represents nitro, lower alkylsulphonyl or arylsulphonyl; m is an integer from 2 to 4 inclusive; n is zero, 1 or 2; and Alk denotes a straight or branched alkylene chain of 1 to 6 carbon atoms. The compounds have therapeutic activity.

11a-Methano-TXA compounds

The present invention provides novel 11a-methano-TXA compounds and intermediates and processs for their preparation. Further provided are methods for using these novel TXA analogs as inhibitors of thromboxane synthetase, rendering these analogs useful for a variety of pharmacological purposes. These pharmacological uses include anti-inflammatory, anti-thromobitc, and anti-asthma indications.